Orexo AB (publ) (C5G F) stock market data APIs
€1.6216
0(0%)
as of May 19, 2026
Try our APIs with
free plan!
Orexo AB (publ) Financial Data Overview
Price chart is built with
Anychart
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Prev. Close
1.6216
Open
1.6216
High
1.6216
Low
1.6216
52 wk Range
1.22-3.825
Market Cap
59 453 K
Shares Outstanding
35 127 K
Revenue
544 M
Beta
0.873
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Orexo AB (publ) data using free add-ons & libraries
Get Orexo AB (publ) Fundamental Data
Orexo AB (publ) Fundamental data includes:
- Net Revenue: 544 M
- EBITDA: -303 300 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-04-28
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Orexo AB (publ) News
New
Orexo's patent win for ZUBSOLV® appealed
UPPSALA, Sweden, July 24, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc.,...
Orexo Q2 2023 Interim Report
UPPSALA, Sweden, July 18, 2023 /PRNewswire/ -- The patent win critical enabler for future growth Q2 2023 highlights › Total net revenues of SEK 157.7 m (147.8) › EBITDA of SEK 5....
Orexo wins patent litigation for ZUBSOLV® in the US
The court found Orexo´s patents valid and infringed by Sun The outcome once again confirms the strength of the company´s intellectual property rights and the ability to develop innovative products ...
Life Science Investor Forum: Presentations Now Available for Online Viewing
Virtual Investor Conferences Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the lead...
Get Orexo AB (publ) fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
